Market Vectors Distributes Quarterly Dividend for Its Pharmaceutical ETF (PPH)

Market Vectors ETF Trust this week distributed the quarterly dividend for its Pharmaceutical ETF (NYSE Arca: PPH), an exchange-traded fund (ETF) which seeks to track an index comprised of the largest, most liquid global pharmaceutical companies. PPH distributed $0.2684 per share for the second quarter. The payable date was July 8th.

“PPH continues to offer investors a single point of access to the largest names in global pharma and the attractive dividends they have historically paid,” said Mike Cohick, ETF Product Manager with Market Vectors. “The pharma growth story continues to be compelling and the income potential of the constituents in the index may continue to interest investors as we head into the second half of the year.”

PPH seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors US Listed Pharmaceutical 25 Index (MVPPHTR), a rules-based index intended to track the overall performance of the largest 25 U.S.-listed pharmaceutical companies. The index methodology favors the largest, most liquid companies in the industry and the portfolio may include both domestic and U.S.-listed foreign companies, allowing for enhanced industry representation.

As of June 28, 2013 the fund’s holdings included:

PPH has a gross expense ratio of 0.41 percent and a net expense ratio of 0.35 percent. Expenses are capped contractually at 0.35% until at least 2/01/14. Cap excludes certain expenses, such as interest.

About Market Vectors ETFs

Market Vectors exchange-traded products have been offered since 2006 and span many asset classes, including equities, fixed income (municipal and international bonds) and currency markets. The Market Vectors family totaled $21.8 billion in assets under management, making it the seventh largest ETP family in the U.S. and tenth largest worldwide as of June 30, 2013.

Market Vectors ETFs are sponsored by Van Eck Global. Founded in 1955, Van Eck Global was among the first U.S. money managers helping investors achieve greater diversification through global investing. Today, the firm continues this tradition by offering innovative, actively managed investment choices in hard assets, emerging markets, precious metals including gold, and other alternative asset classes.

Investments concentrated in the pharmaceutical sector may be subject to more volatility than investments in a diverse group of sectors. They are subject to the risks associated with the sector including, among others, costs associated with research and development, intellectual property rights and regulatory approval by the U.S. Food and Drug Administration. Additionally, the Fund is subject to changes in economic and political conditions, foreign currency fluctuations, changes in foreign regulations and other risks inherent to international investing. Investing in securities of medium-sized companies may involve greater risk than is customarily associated with investing in large companies. The Fund is considered non-diversified and may be subject to greater risks than a diversified fund. Investors should be willing to accept a high degree of volatility and the potential of significant loss. See the Fund’s prospectus for more complete information regarding investment risks.

Investing involves substantial risk and high volatility, including possible loss of principal. An investor should consider the investment objective, risks, charges and expenses of the Fund carefully before investing. Please refer to the prospectus for complete risk information. To obtain a prospectus and summary prospectus, which contains this and other information, call 888.MKT.VCTR or visit marketvectorsetfs.com. Please read the prospectus and summary prospectus carefully before investing.

Van Eck Securities Corporation, Distributor, 335 Madison Avenue, New York, NY 10017